About
About Nippon Shinyaku Co., Ltd
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc. to develop ATSN-101 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and Regenex Bio Inc. to develop RGX-121 and RGX-111 for the treatment of mucopolysaccharidosis type I and II. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Visit company website
5 years, 6 months ago
Nippon Shinyaku Co., Ltd is currently in a long term uptrend where the price is trading 11.2% above its 200 day moving average.
From a valuation standpoint, the stock is 93.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.5.
Nippon Shinyaku Co., Ltd's total revenue rose by 10.7% to $34B since the same quarter in the previous year.
Its net income has increased by 95.0% to $7B since the same quarter in the previous year.
Based on the above factors, Nippon Shinyaku Co., Ltd gets an overall score of 4/5.